DOCSLIB.ORG

Biographical Profile

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biographical Profile Biographical profile Trevor W. Robbins, CBE, FRS FMedSci Trevor Robbins is Professor of Cognitive Neuroscience (since 1997) and Head of the Department of Experimental Psychology at the University of Cambridge (since 2002). He is also Director of the Cambridge University MRC-Wellcome Trust funded Behavioural and Clinical Neuroscience Institute (BCNI), the main objective of which is to inter-relate basic and clinical research in psychiatry and neurology. Professor Robbins is a Fellow of the British Psychological Society, the Academy of Medical Sciences, and the Royal Society. He has published over 600 peer-reviewed papers and 70 chapters in scientific journals and has co-edited 6 books. He is one of the most cited neuroscientists according to the International Statistical Institute (ISI). He was awarded the European Behavioural Pharmacology Society’s inaugural Distinguished Achievement Award in 2001 and in 2005, he shared the IPSEN Fondation Prize in Neuronal Plasticity and was the Kavli Distinguished International Scientist Lecturer at the Society for Neuroscience annual meeting the same year. Recently, this year he was jointly awarded the Distinguished Scientific Contribution Award of the American Psychological Association. 1 CURRICULUM VITAE of Trevor William Robbins Place and date of birth: London, U.K. 26 November, 1949 Nationality: British Status Married, Barbara J Sahakian, 2 daughters Jacqueline and Miranda Address Dept. of Experimental Psychology, Downing Street, Cambridge CB2 3EB U.K Tel: 44-1223 333551: fax 44-1223 333564; e-mail [email protected] Degrees University of Cambridge, Jesus College. B.A. (Nat. Sciences Tripos, Psychology) Pt. II, 1971 (1st Class Hons); M.A., 1974; Ph.D., 1975 Honours CBE, 2012 University Appointments 1973-1978 University Demonstrator in Experimental Psychology, Univ. of Cambridge 1978-1992 University Lecturer in Experimental Psychology, Univ. of Cambridge 1992-1997 Reader in Cognitive Neuroscience, Univ. of Cambridge 1997- Professor of Cognitive Neuroscience, Univ. of Cambridge 2002- Professor of Experimental Psychology and Head of Department, Univ. of Cambridge Other Appointments 1976 Research Fellow, Harvard Medical School (Prof. P B Dews) 1981 Visiting Research Associate, Salk Research Inst. (Drs. F E Bloom & G F Koob) 1987 Research Fellow, Inst. of Neurology, (Profs C D Marsden/ E Warrington). 1990- Fellow, British Psychological Society 1991- Fellow, Downing College, Cambridge 1992-1994 President, European Behavioural Pharmacology Society (EBPS) 1996-1998 President, British Association for Psychopharmacology 1999- Fellow, Academy of Medical Sciences 2002- Director of the Cambridge Behavioural and Clinical Neuroscience Institute (MRC and Wellcome Trust) 2005- Fellow of the Royal Society 2006-2008 Member of RAE 2008 Panel 9 2007- Member of the Neuroscience Institute (G Edelman), San Diego California USA Awards etc : 1971 Titular Scholarship, Jesus College, 1971-1973 S.R.C. Studentship 1982 British Psychological Society - Spearman Medal for outstanding research 1996 D M Marquis award for best paper in Behavioral euroscience (American Psychological Association) 2001 ISI 100 most-cited Neuroscientists list and diploma 2002 EBPS Distinguished Achievement Award 2004 Collège de France Lecturer and medalist 2005 Foundation IPSEN Neuronal Plasticity Prize 2006 Fred Kavli Distinguished International Lecturer (Society for Neuroscience) 2011 Distinguished Scientific Contribution, American Psychological Association Membership of Editorial Boards : 1980- Managing Editor Psychopharmacology 1996-2000 Associate Editor of the APA journal Behavioral euroscience 2003- Advisory Editorial Board of 11 other journals, including Science Membership of Research and Grant Committees (since 1990) 1989-1993 Medical Research Council: Neuroscience Board (Vice Chairman 1992-3) Chairman of MRC Review on the 'Basis of Drug Dependence' (publ. 1994) 1995-1999 Chairman: Medical Research Council Neuroscience Board 1988-1992 Medical Research Council: Training Awards Panel 1995-1999 Medical Research Council: Member 1992- 2001 Parkinson's Disease Society: Medical Advisory Panel 2 1995-2002 Governing Body of Babraham Institute: Chairman Scientific Advisory Panel 2000- J.M. McDonnell Foundation: Advisory Board 2001-2008 Chair: Advisory Board Inst. of Psychiatry Centre for Social, Developmental and Genetic Psychiatry 2002-2005 Advisory Board member: Vrije University Centre for Neuroscience and Functional Genomic 2002-2008 Advisory Board member: University of Nottingham Neuroscience Centre 2003-2009 Beit Memorial Scientific Advisory Committee 2004-2006 Project Leader, Technology Foresight, Department of Trade and Industry, U. K. Brain Science, Addiction and Drugs. 2006-2008 Academy of Medical Sciences Report on Brain Science, Addiction and Drugs 2006-2009 MRC Milstein Committee 2007-2009 Scientific Advisory Committee, Wellcome Trust Centre for Cognitive Neuroimaging 2007-2011 Scientific Advisory Committee, UCLA Genes and Behavior NIH Consortium 2007-2011 Scientific Advisory Committee, Yale University Stress and Behavior Consortium 2007-2010 Royal Society Sectional Committee 8; Chair 2008-2010 2007- Advisory Board Member: Eli Lilly Centre for Cognitive Neuroscience, Erlwood, Surrey U.K. 2010- Royal Society Council Membership of Committees for Learned Societies 1985-1996 Committee Member - British Association for Psychopharmacology 1986-1988 European Behavioural Pharmacology Society Committee (Founder Member) 1988-1991 Committee Member - European Brain and Behaviour Society 1992-1994 European Behavioural Pharmacology Society (EBPS): President 1996-1998 President: British Association for Psychopharmacology 1996-1999 European Neuroscience Association: Council Member 2009- 2011 President: British Neuroscience Association Organisation of Recent Research Symposia and Meetings Co-Convenor of BAP. One-day meeting, Oct. 1995: 'Psychopharmacology of Prefrontal Cortex'; Co- Convenor of Royal Society Discussion Meeting: 'Executive and Cognitive Functions of the Prefrontal Cortex, March 1996; CIBA Foundation Meeting: 'Cognitive Functions of the Basal Ganglia'. Convenor Euroconference on Perturbation of the Trace, Evian, France, May 2002; Iversen Reunion symposium, Cambridge, 2006; Royal Society Discussion Meeting: Neurobiology of Drug Addiction: New Vistas, 2008; Cambridge Neuroscience Symposium, Cambridge 2007, 2009. Britsh Neuroscience Association, Biennial meeting, Harrogate UK April 2011. Colloquia and invited lectures on research Over 400 since 1973. Recent examples: Hebb Lecture Dalhousie University, 2004; Plenaries or Keynote Lectures at FENS, Paris 2002; Gordon Conference, Oxford, 2003; EBPS Biennial meeting, Antwerp, 2003; NIMH MATRICS meeting, 2004; British Neuroscience Association (Trends in Neuroscience Lecture), College on Problems of Drug Dependence (Orlando 2005); French Neuroscience Society (Lille, 2005); Scandinavian Neuropsychopharmacology Society, 2005; Fred Kavli Distinguished International Lecturer, Society for Neuroscience (SFN), Washington, 2005; Harold Cooper Lecture, University of Texas, Houston, 2006; University of Bath Centenary Series Lecture; Microsoft, San Francisco, 2007; John Flynn Memorial Lecture, Yale 2008; Eugene Bleuler Symposium (Zurich), 2008; Staglin Mental Health Music Festival, 2008 (Napa Valley); Institute of Neuroscience (San Diego), 2009; Royal Society of Medicine, 2009; Royal College of Psychiatry (Edinburgh), 2009; Sluckin Lecture, Leicester, 2009; International Behavioural Neuroscience Society, Plenary (Nassau), 2009; International Society for Research into Impulsivity, Plenary Lecture San Diego, 2009; European Congress of Psychology, Keynote (Oslo), 2009; ECNP Symposium on Compulsivity Amsterdam, 2010; Britsh Association for Psychopharmacology, Harrogate 2010, Guest Lecture; British Neuropsychiatric Association, Keynote Lecture 2011. American Psychological Association, Distinguished Scientific Contribution Lecture, Washington D.C. 2011. Otto Wolf Lecture, UCL, Sept. 2011. Volker-Henn Plenary, Zurich Sept. 2011. NIMH Seminar Nov. 2011. UCSD Psychology Seminar, Nov. 2011. Research Interests Cognitive and behavioural neuroscience: translation to neurological and neuropsychiatric disorders. Neuropsychology and psychopharmacology. Functions of fronto-striatal-limbic systems in cognitive and executive functions, and their modulation by monoaminergic systems. Special interests in addiction and cognitive enhancement. Recent Major Research Grants (1996-) 1999-2004 Robbins (PI), Roberts, Sahakian, Everitt Neural substrates of decision-making and impulsivity: comparative studies in rats, monkeys and humans. Wellcome Trust. Programme Grant, £1.4M 3 2001-2004 Everitt (PI), Pennartz, Robbins, McNaughton Cell assembly interactions between connected brain areas during learning and memory consolidation. Human Science Frontier Project Grant $1,000,000 (approx) 2001-2006 Everitt (PI), Dickinson, Robbins, The persistence and prevention of drug addiction; neurobehavioural mechanisms. MRC programme grant £1.5M 2002-2007 Robbins (PI), Broers, Behavioural and Clinical Neuroscience. MRC centre grant £1.9M 2003-2008 Bullmore (PI), Fletcher, Suckling, Robbins et al., Wavelets, fractals and fMRI of brain adaptivity. National Institutes of Health (Human Brain Project) $1.35M 2005-2007 Robbins (PI), Roberts, Phelps, Study panel on affect, learning and decision-making. James McDonnell Foundation, NY University, approximately $100,000 plus $50,000 cost extension until 2007 2005-2007 Dalley (PI), Everitt, Robbins, An investigation
Load more

Recommended publications
  • The Use of Non-Human Primates in Research in Primates Non-Human of Use The
    The use of non-human primates in research The use of non-human primates in research A working group report chaired by Sir David Weatherall FRS FMedSci Report sponsored by: Academy of Medical Sciences Medical Research Council The Royal Society Wellcome Trust 10 Carlton House Terrace 20 Park Crescent 6-9 Carlton House Terrace 215 Euston Road London, SW1Y 5AH London, W1B 1AL London, SW1Y 5AG London, NW1 2BE December 2006 December Tel: +44(0)20 7969 5288 Tel: +44(0)20 7636 5422 Tel: +44(0)20 7451 2590 Tel: +44(0)20 7611 8888 Fax: +44(0)20 7969 5298 Fax: +44(0)20 7436 6179 Fax: +44(0)20 7451 2692 Fax: +44(0)20 7611 8545 Email: E-mail: E-mail: E-mail: [email protected] [email protected] [email protected] [email protected] Web: www.acmedsci.ac.uk Web: www.mrc.ac.uk Web: www.royalsoc.ac.uk Web: www.wellcome.ac.uk December 2006 The use of non-human primates in research A working group report chaired by Sir David Weatheall FRS FMedSci December 2006 Sponsors’ statement The use of non-human primates continues to be one the most contentious areas of biological and medical research. The publication of this independent report into the scientific basis for the past, current and future role of non-human primates in research is both a necessary and timely contribution to the debate. We emphasise that members of the working group have worked independently of the four sponsoring organisations. Our organisations did not provide input into the report’s content, conclusions or recommendations.
    [Show full text]
  • Cognitive Enhancement and the Emergence of Personhood
    http://dx.doi.org/10.5007/1677-2954.2021.e80030 FROM THE NECESSITY OF BEING HUMAN TO THE POSSIBILITY OF PURSUING A GOOD LIFE: COGNITIVE ENHANCEMENT AND THE EMERGENCE OF PERSONHOOD GIOVANA LOPES1 (UNIVERSITÀ DI BOLOGNA/Italia) BRUNELLO STANCIOLI2 (UFMG/Brasil) ABSTRACT Throughout human history, cognition enhancement has not only been a constant, but also imperative for our species evolution and well-being. However, philosophical assumptions that enhancing cognition by biomedical means goes against some immutable human nature, combined with the lack of conclusive data about its use on healthy individuals and long-term effects, can sometimes result in prohibitive approaches. In this context, the authors seek to demonstrate that cognition enhancement, whether by “natural” or biotechnological means, is essential to the emergence of personhood, and to existence of an autonomous life that is guided by a person’s own conception of the good. In order to do so, the main possibilities of enhancing cognition through biotechnologies, along with its benefits and potentialities, as well as its risks and limitations, will be presented. Following Savulescu and Sandberg’s account on cognitive enhancement, it will be argued that it constitutes both a consumption good, being desirable and happiness-promoting to have well-functioning cognition, and a capital good that reduces risks, increases earning capacity, and forms a key part of human capital. Finally, having in mind that progress in the field of biotechnology aimed at cognition enhancement may improve a person’s (and society’s) well-being, the authors will argue that further research in the field is necessary, especially studies that takes into consideration dimensions such as dose, individual characteristics and task characteristics.
    [Show full text]
  • TREVOR W. ROBBINS, CBE FRS Fmedsci Fbpss
    TREVOR W. ROBBINS, CBE FRS FMedSci FBPsS Professor of Cognitive Neuroscience and Experimental Psychology Trevor Robbins is accepting applications for PhD students. Email: [email protected] Office Phone: +44 (0)1223 (3)33551 Websites: • http://www.neuroscience.cam.ac.uk/directory/profile.php?Trevor Download as vCard Biography: Trevor Robbins was appointed in 1997 as the Professor of Cognitive Neuroscience at the University of Cambridge. He was elected to the Chair of Experimental Psychology (and Head of Department) at Cambridge from October 2002. He is also Director of the Behavioural and Clinical Neuroscience Institute (BCNI), jointly funded by the Medical Research Council and the Wellcome Trust. The mission of the BCNI is to inter-relate basic and clinical research in psychiatry and neurology for such conditions as Parkinson's, Huntington's, and Alzheimer's diseases, frontal lobe injury, schizophrenia, depression, drug addiction and developmental syndromes such as attention deficit/hyperactivity disorder. Trevor is a Fellow of the British Psychological Society (1990), the Academy of Medical Sciences (2000) and the Royal Society (2005). He has been President of the European Behavioural Pharmacology Society (1992-1994) and he won that Society's inaugural Distinguished Scientist Award in 2001. He was also President of the British Association of Psychopharmacology from 1996 to 1997. He has edited the journal Psychopharmacology since 1980 and joined the editorial board of Science in January 2003. He has been a member of the Medical Research Council (UK) and chaired the Neuroscience and Mental Health Board from 1995 until 1999. He has been included on a list of the 100 most cited neuroscientists by ISI, has published over 600 full papers in scientific journals and has co-edited seven books (Psychology for Medicine: The Prefrontal Cortex; Executive and Cognitive Function: Disorders of Brain and Mind 2:Drugs and the Future: The Neurobiology of Addiction; New Vistas.
    [Show full text]
  • College Annual Report and Accounts 2013-2014
    DOWNING COLLEGE CAMBRIDGE ANNUAL REPORT AND ACCOUNTS for the financial year ending 30 June 2014 The West Range ©Tim Rawle www.dow.cam.ac.uk 2 Contents 5. Financial Highlights 6. Members of the Governing Body 9. Officers and Principal Professional Advisors 11. Report of the Governing Body 67. Financial Statements 77. Principal Accounting Statements 78. Consolidated Income & Expenditure Account 79. Consolidated Statement of Total Recognised Gains and Losses 80. Consolidated Balance Sheet 82. Consolidated Cashflow Statement 85. Notes to the Accounts 3 4 Financial HIGHlIGHtS 2014 2013 2012 £ £ £ Highlights Income Income 10,155,889 9,663,733 9,239,544 Donations and Benefactions Received 5,292,916 3,124,484 2,304,365 Financial | Conference Services Income 2,042,832 2,130,085 1,875,620 Operating Surplus/(Deficit) 320,009 336,783 306,969 2014 Cost of Space (£ per m2) £150.87 £150.20 £156.65 College Fees: June Publicly Funded Undergraduates £4,068/£4,500 £3,951/£4,500 £3,951 30 Privately Funded Undergraduates £7,350 £6,999 £6,000 Graduates £2,424 £2,349 £2,289 Ended loss on College Fee per Student £2,436 £2,630 £1,995 Year Capital Expenditure Investment in Historical Buildings 1,751,811 573,388 446,851 Investment in Student Accommodation 1,499,507 740,562 2,784,000 Assets Free Reserves 8,349,966 13,372,300 11,499,498 Investment Portfolio 35,775,344 34,917,793 31,785,279 Spending Rule Amount 1,617,819 1,543,197 1,505,631 total Return 7.6% 9.2% 6.2% total Return: 3 year average 7.7% 10.3% 10.6% Return on Property 5.8% 7.6% 11.4% Return on Property:
    [Show full text]
  • Human Functional Brain Imaging 1990–2009
    Portfolio Review Human Functional Brain Imaging 1990–2009 September 2011 Acknowledgements The Wellcome Trust would like to thank the many people who generously gave up their time to participate in this review. The project was led by Claire Vaughan and Liz Allen. Key input and support was provided by Lynsey Bilsland, Richard Morris, John Williams, Shewly Choudhury, Kathryn Adcock, David Lynn, Kevin Dolby, Beth Thompson, Anna Wade, Suzi Morris, Annie Sanderson, and Jo Scott; and Lois Reynolds and Tilli Tansey (Wellcome Trust Expert Group). The views expressed in this report are those of the Wellcome Trust project team, drawing on the evidence compiled during the review. We are indebted to the independent Expert Group and our industry experts, who were pivotal in providing the assessments of the Trust’s role in supporting human functional brain imaging and have informed ‘our’ speculations for the future. Finally, we would like to thank Professor Randy Buckner, Professor Ray Dolan and Dr Anne-Marie Engel, who provided valuable input to the development of the timelines and report. The2 | Portfolio Wellcome Review: Trust Human is a Functional charity registeredBrain Imaging in England and Wales, no. 210183. Contents Acknowledgements 2 Key abbreviations used in the report 4 Overview and key findings 4 Landmarks in human functional brain imaging 10 1. Introduction and background 12 2 Human functional brain imaging today: the global research landscape 14 2.1 The global scene 14 2.2 The UK 15 2.3 Europe 17 2.4 Industry 17 2.5 Human brain imaging
    [Show full text]
  • 2017 Annual Report
    RESEARCH FOR RECOVERY ACCELERATING PATHWAYS TO MENTAL HEALTH BRAIN & BEHAVIOR RESEARCH FOUNDATION 2017 ANNUAL REPORT Awarding research grants to develop improved treatments, cures, and methods of prevention for mental illness. www.bbrfoundation.org 1 FROM DISCOVERY TO RECOVERY Mission The Brain & Behavior Research Foundation (BBRF) is committed to alleviating the suffering caused by mental illness by awarding grants that will lead to advances and breakthroughs in scientific research. Vision To dramatically improve the lives of those living with mental illness and ultimately enable them to live full, happy, and productive lives. 100% of all donor contributions for research are invested in grants that lead to discoveries in understanding the causes and improving treatments for brain and behavior disorders in children and adults including addiction, ADHD, anxiety, autism, bipolar disorder, borderline personality disorder, depression, eating disorders, OCD, PTSD, schizophrenia, and suicide prevention. For 30 years we have awarded more than $380 million, to more than 4,500 scientists carefully selected by our prestigious Scientific Council. 2 ANNUAL REPORT 2017 BBRF GRANTS SUPPORT THE MOST PROMISING IDEAS IN BRAIN RESEARCH. We invest in: Basic Research to understand what happens in the brain to cause mental illness New Technologies to advance or create new ways of studying and understanding the brain Diagnostic Tools And Early Intervention to recognize early signs of mental illness and begin treatment as early as possible Next-Generation Therapies
    [Show full text]
  • Trustees' Report and Financial Statements
    The Royal Society Trustees’ report and financial statements for the year ended 31 March 2013 Trustees’ report and financial statements For the year ended 31 March 2013 Trustees Statutory Auditor The Trustees of the Society are the BDO LLP members of its Council, who are elected 55 Baker Street by the Fellowship. Council is chaired by the London President of the Society. During 2012/13, W1U 7EU the members of Council were as follows: Bankers President The Royal Bank of Scotland Sir Paul Nurse 1 Princess Street London Foreign Secretary EC2R 8BP Professor Martyn Poliakoff CBE Investment Managers Physical Secretary Rathbone Brothers PLC Professor John Pethica 1 Curzon Street London Biological Secretary W1J 5FB Dame Jean Thomas DBE Internal Auditors Treasurer PricewaterhouseCoopers LLP Sir Peter Williams * Cornwall Court Professor Anthony Cheetham ** 19 Cornwall Street Members of Council Birmingham Professor Gillian Bates B3 2DT Professor Andrew Blake * Professor Geoffrey Boulton OBE ** Sir John Beddington CMG ** Registered charity No 207043 Dr Simon Campbell CBE Professor John Collinge CBE Registered Address Professor Athene Donald DBE ** 6 – 9 Carlton House Terrace Professor Peter Donnelly * London SW1Y 5AG Professor Carlos Frenk ** Professor Alexander Halliday royalsociety.org Professor Judith Howard CBE Professor Frances Kirwan ** Professor Ottoline Leyser CBE ** Dr Robin Lovell-Badge Professor John McWhirter * Professor Kim Nasmyth * Professor Roger Owen ** Dame Linda Partridge * Professor Timothy Pedley ** Professor Trevor Robbins * Professor Wilson Sibbett * Sir Christopher Snowden * Professor Nicholas Tonks Professor John Wood ** * up to 30 November 2012 ** since 1 December 2012 Executive Director Dr Julie Maxton Cover: Bicontinuous, interfacially jammed emulsion gel capsule. Courtesy of Dr Paul Clegg, Industry Fellow.
    [Show full text]
  • Treating Addiction in the Clinic, Not the Courtroom: Using Neuroscience and Genetics to Abandon the Failed War on Drugs
    TREATING ADDICTION IN THE CLINIC, NOT THE COURTROOM: USING NEUROSCIENCE AND GENETICS TO ABANDON THE FAILED WAR ON DRUGS TENEILLE R. BROWN* ABSTRACT The opioid addiction epidemic has been one of the most overwhelming public health crises our country has faced. It has also created a legal crisis, as its aftermath spills over into the criminal, civil, and family courts. One estimate puts its cost to the U.S. economy at over $500 billion in 2015.1 More than a hundred people die every day from an opioid overdose,2 with that number likely increasing during the COVID-19 pandemic. The pressure on law enforcement, emergency responders, behavioral health services, and jails is crippling our cities and counties. This Article is an attempt to relieve some of that pressure by doing something we should have done a long time ago: change the way we think about and treat addiction. At least 2.3 million people in the United States have opioid use disorder (OUD), yet over 60% do not have access to evidence-based treatment.3 Of the over 14,000 drug treatment programs in the country, most are not staffed with a single licensed medical practitioner.4 Close your eyes and try to imagine 60% of people with lung cancer not having access to chemotherapy or radiation, or sending your mother to a cancer clinic that was not staffed with * Teneille R. Brown, J.D., is a Professor of Law at the University of Utah, S.J. Quinney College of Law, and an adjunct Professor in the Department of General Internal Medicine.
    [Show full text]
  • BNA2015-Abstract-Book.Pdf
    BNA2015: Festival of Neuroscience Poster Abstracts 12‐14 April 2015 EICC, Edinburgh, UK Citations The recommended citation for an abstract in this volume is as follows: British Neurosci. Assoc. Abstr., Vol. 23: Pxx, 2015 ISSN 1345‐8301 2015 Contents Sunday 12 April 2015 - Poster Session 1 Page Floor plan 4 Theme A: Development 5 B: Molecular, Cellular and Synaptic Mechanisms 24 C: Sensory and Motor Systems 68 D: Learning, Memory and Cognition 104 F: Nervous System Disorders 173 G: Methods and Techniques 234 H: Autonomic Nervous System 251 Monday 13 April – Poster Session 2 Page Floor plan 261 Theme A: Development 262 B: Molecular, Cellular and Synaptic Mechanisms 286 C: Sensory and Motor Systems 332 D: Learning, Memory and Cognition 368 E: Sleep, Circadian and Neuroendocrine Mechanisms 434 F: Nervous System Disorders 453 G: Methods and Techniques 518 Tuesday 14 April – Poster Session 3 Page Floor plan 537 Theme A: Development 538 B: Molecular, Cellular and Synaptic Mechanisms 560 C: Sensory and Motor Systems 605 D: Learning, Memory and Cognition 637 E: Sleep, Circadian and Neuroendocrine Mechanisms 704 F: Nervous System Disorders 723 G: Methods and Techniques 782 Conflict of interest declarations 798 Poster Reference Explanation P2-F-012 Poster board number Day Theme 1=Sunday A: Development 2=Monday B: Molecular, Cellular and Synaptic Mechanisms 3=Tuesday C: Sensory and Motor Systems D: Learning, Memory and Cognition E: Sleep, Circadian and Neuroendocrine Mechanisms F: Nervous System Disorders G: Methods and Techniques H: Autonomic Nervous
    [Show full text]
  • Acknowledgment of Reviewers, 2009
    Proceedings of the National Academy ofPNAS Sciences of the United States of America www.pnas.org Acknowledgment of Reviewers, 2009 The PNAS editors would like to thank all the individuals who dedicated their considerable time and expertise to the journal by serving as reviewers in 2009. Their generous contribution is deeply appreciated. A R. Alison Adcock Schahram Akbarian Paul Allen Lauren Ancel Meyers Duur Aanen Lia Addadi Brian Akerley Phillip Allen Robin Anders Lucien Aarden John Adelman Joshua Akey Fred Allendorf Jens Andersen Ruben Abagayan Zach Adelman Anna Akhmanova Robert Aller Olaf Andersen Alejandro Aballay Sarah Ades Eduard Akhunov Thorsten Allers Richard Andersen Cory Abate-Shen Stuart B. Adler Huda Akil Stefano Allesina Robert Andersen Abul Abbas Ralph Adolphs Shizuo Akira Richard Alley Adam Anderson Jonathan Abbatt Markus Aebi Gustav Akk Mark Alliegro Daniel Anderson Patrick Abbot Ueli Aebi Mikael Akke David Allison David Anderson Geoffrey Abbott Peter Aerts Armen Akopian Jeremy Allison Deborah Anderson L. Abbott Markus Affolter David Alais John Allman Gary Anderson Larry Abbott Pavel Afonine Eric Alani Laura Almasy James Anderson Akio Abe Jeffrey Agar Balbino Alarcon Osborne Almeida John Anderson Stephen Abedon Bharat Aggarwal McEwan Alastair Grac¸a Almeida-Porada Kathryn Anderson Steffen Abel John Aggleton Mikko Alava Genevieve Almouzni Mark Anderson Eugene Agichtein Christopher Albanese Emad Alnemri Richard Anderson Ted Abel Xabier Agirrezabala Birgit Alber Costica Aloman Robert P. Anderson Asa Abeliovich Ariel Agmon Tom Alber Jose´ Alonso Timothy Anderson Birgit Abler Noe¨l Agne`s Mark Albers Carlos Alonso-Alvarez Inger Andersson Robert Abraham Vladimir Agranovich Matthew Albert Suzanne Alonzo Tommy Andersson Wickliffe Abraham Anurag Agrawal Kurt Albertine Carlos Alos-Ferrer Masami Ando Charles Abrams Arun Agrawal Susan Alberts Seth Alper Tadashi Andoh Peter Abrams Rajendra Agrawal Adriana Albini Margaret Altemus Jose Andrade, Jr.
    [Show full text]
  • Trevor W Robbins CBE FRS Fmedsci Phd Trevor Has Been Professor Of
    Trevor W Robbins CBE FRS FMedSci PhD Trevor has been Professor of Cognitive Neuroscience at the University of Cambridge from 1997. He was also Professor of Expt. Psychology and Head of the Dept. of Psychology from 2002-2017. He has been based in Cambridge for most of his scientific career, receiving his PhD there in 1975. He is a Fellow of the British Psychological Society (1990), the British Pharmacological Society (2017), the Academy of Medical Sciences (2000), and the Royal Society (2005), the most prestigious science society in the U.K. He has published over 800 full papers, with an H index of about 196. He has co-edited eight books, most recently Translational Neuropsychopharmacology (Springer, 2016)). He edits Psychopharmacology (since 1980) and Current Opinion in the Behavioral Sciences and is an editorial advisor for Science. Trevor directs the ‘Behavioural and Clinical Neuroscience Institute’ (BCNI) (funded by the MRC and Wellcome Trust) the mission of which is to enhance translation from basic to clinical neuroscience with particular reference to impulsive-compulsive disorders, including drug addiction. His interest in translation began with his co-invention in 1987 of the CANTAB computerized neuropsychological battery, which is currently used in over 700 institutes and clinical centres world-wide. Among several prizes, he received the Distinguished Scientific Contribution Award for 2011 from the American Psychological Association. He was made a CBE in the U.K. New Year’s Honours list. in 2012 "for services to medical research". In 2014 he shared the ‘Brain Prize’ of the Grete Lundbeck European Brain Research Foundation, the most valuable in neuroscience, for his work on human mental disorders.
    [Show full text]
  • The Relative Contribution of Goal-Directed and Habit Systems To
    Psychiatria Danubina, 2017; Vol. 29, Suppl. 3, pp 203-213 Conference paper © Medicinska naklada - Zagreb, Croatia THE RELATIVE CONTRIBUTION OF GOAL-DIRECTED AND HABIT SYSTEMS TO PSYCHIATRIC DISORDERS Sophie Woodhead1,2 & Trevor Robbins3 1Clare College, Cambridge, UK 2Imperial College Medical School, London, UK 3Department of Experimental Psychology University of Cambridge, Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK SUMMARY Psychiatric disorders may be caused by underlying imbalances between goal-directed and habit systems in the brain. Numerous studies have aimed to establish whether this is because of a goal-directed system deficit, enhanced habit system, or both. This transdiagnostic approach to studying psychiatric disorders is increasingly popular. Maladaptive habitual behaviour is present in many disorders. It is the principal observation in disorders of compulsivity and is also present in other psychiatric disorders that are not primarily characterised by compulsive behaviour. The psychopathology that causes these disorders might be similar and could be targeted with specific treatment. Traditional categorical classification systems of psychiatric disorders do not reflect similarities in neurobiological dysfunction. The comorbidity and overlap between psychiatric disorders means that a dimensional classifications system based on underlying brain system dysfunction might be more appropriate. In this paper, the neural and neuromodulatory systems that contribute to goal-directed and habit systems are discussed. Account is taken of model-based and model-free computational learning mechanisms that are thought to give rise to goal-directed and habitual control respectively. Different psychiatric disorders that have a deficit in goal-directed behaviour or habit systems are then explored to see if there are similarities in the underlying neural systems despite differences in clinical presentation.
    [Show full text]